Lupus erythematosus
☆ Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
It ferskynt as in bytsje pearse erythema.
De flinterútslach dy't typysk op it gesicht ferskynt.
References
It identifisearjen en klassifisearjen fan cutaneous lupus erythematosus (CLE) stelt diagnostyske útdagings, en ûnderskiedt it fan systemic lupus erythematosus mei belutsenens fan 'e hûd. Resinte stúdzjes jouwe ljocht op genetyske, miljeu- en immunologyske faktoaren dy't CLE ûnderlizze. Drug-induksje is spesifyk ûntstien as ien fan 'e wichtichste triggers foar CLE. Behanneling omfettet aktuele en systemyske terapyen, ynklusyf belofte biologyske medisinen (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , mei oantoand effektiviteit yn klinyske proeven.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) behannelet ferskate hûdproblemen, wêrfan guon kinne keppele wurde oan bredere sûnensproblemen. It is yndield yn ferskate soarten, lykas acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE bestiet út discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus is in groep autoimmune sykten dy't ferskate dielen fan it lichem kinne beynfloedzje. Guon soarten, lykas systemic lupus erythematosus (SLE) , beynfloedzje meardere organen, wylst oaren, lykas cutaneous lupus erythematosus (CLE) , benammen de hûd beynfloedzje. Wy kategorisearje ferskate soarten CLE basearre op in miks fan klinyske tekens, weefselûndersyk, en bloedtests, mar d'r is in protte fariaasje tusken yndividuen. Hûdproblemen ûntwikkelje faak troch faktoaren lykas bleatstelling oan sinneljocht, smoken, of bepaalde medisinen.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
De oarsaak fan lupus erythematosus is net dúdlik. Under identike twilling, as ien wurdt troffen is d'r in 24% kâns dat de oare ek sil wêze. Froulike sekshormonen, sinneljocht, smoken, vitamine D-tekoart, en bepaalde ynfeksjes wurde ek leaud dat it risiko ferheegje.
Behannelingen kinne NSAID's, corticosteroids, immunosuppressanten, hydroxychloroquine, en methotrexate omfetsje. Hoewol corticosteroids binne effektyf, lange-termyn gebrûk resultearret yn kant effekten.